阿德福韦酯联合干扰素对慢性乙型病毒性肝炎患者血清IL-17的影响  

The effectiveness of adefovir dipivoxil plus Interferon on serum IL-17 in patients with chronic hepatitis B

作　　者：李玉魁[1] 陈疏敏[2] 

机构地区：[1]河南省人民医院感染科 [2]河南省中医院

出　　处：《中国实用医药》2013年第22期15-17,共3页China Practical Medicine

摘　　要：目的探讨阿德福韦酯联合干扰素对慢性乙肝患者血清白细胞介素-17(IL-17)的影响。方法 92例慢性乙肝患者随机分为两组,观察组46例,对照组46例,对照组采用阿德福韦酯治疗,观察组采用干扰素联合阿德福韦酯治疗,治疗12月后观察疗效。治疗前后测定血清IL-17。结果观察组患者的ALT复常率、HBV-DNA阴转率和HbeAg阴转率均高于对照组(P<0.05)。两组治疗后患者的血清IL-17均有明显降低,并且治疗后与对照组比较,观察组降低更明显(P<0.05)。结论阿德福韦酯联合干扰素可以通过降低IL-17表达改善慢性乙肝病情。Objective To study the effectiveness of adefovir dipivoxil plus interferon on serum interleukin-17（IL-17） in patients with chronic hepatitis B.Methods 92 patients with chronic hepatitis B were randomly divided into two groups,the observation group（n=46 cases） and the control group（n=46 cases）.The patients in the control group were treated through adefovir dipivoxil,while the patients in the observation group were treated through interferon plus adefovir dipivoxil for 12 months.Serum IL-17 were detected before and after treatment.Results ALT normalization,HBV-DNA negative rate and HbeAg negative rate in the observation group were higher these in the control group（P＆lt; 0.05）.Serum IL-17 in both groups were significantly decreased after treatment.It in the observation group was more significantly decreased than that in the control group（P＆lt; 0.05）.Conclusion Adefovir dipivoxil plus interferon can improve chronic hepatitis B through decreasing IL-17.

关 键 词：慢性乙肝 阿德福韦酯 干扰素 白细胞介素-17 

分 类 号：R512.62[医药卫生—内科学]